- In March 2024, Zoetis Inc., a global leader in animal health, announced the launch of a new long-acting injectable corticosteroid product designed for use in companion animals suffering from chronic inflammatory and allergic conditions. This formulation allows for reduced dosing frequency, enhancing treatment compliance and pet comfort. The product reflects Zoetis’ commitment to expanding its companion animal portfolio with advanced therapies that address both clinical efficacy and owner convenience
- In February 2024, Elanco Animal Health introduced a next-generation corticosteroid combination therapy for livestock, targeting respiratory inflammation and stress-related conditions in cattle. The dual-action injectable solution received regulatory approval in several Latin American markets and is expected to help farmers reduce animal downtime while improving herd health outcomes. This development aligns with Elanco's strategic focus on innovation in productivity-enhancing therapeutics for food-producing animals
- In January 2024, Boehringer Ingelheim Animal Health partnered with veterinary universities in Europe to conduct real-world clinical trials on a new topical corticosteroid formulation for treating equine dermatitis. The trials aim to validate the safety and efficacy of this non-invasive treatment approach, providing veterinarians with more user-friendly options for large animals. The collaboration underscores Boehringer Ingelheim’s investment in evidence-based product development and field-relevant veterinary solutions
- In November 2023, Virbac SA launched an educational campaign in Asia-Pacific to promote responsible corticosteroid use in small animal practice. The campaign includes training modules, clinical guidelines, and product literature targeting veterinarians in India, Southeast Asia, and Australia. The initiative addresses growing concerns over overuse and misuse of corticosteroids, promoting safer prescribing practices while supporting Virbac’s corticosteroid product lines in emerging markets
- In October 2023, Vetoquinol SA received approval for a novel corticosteroid-based intra-articular injectable in Canada and select EU markets. Specifically formulated for canine osteoarthritis, the product offers sustained anti-inflammatory effects with a single joint injection, reducing the need for oral medications and improving animal mobility. This advancement reflects Vetoquinol’s emphasis on pain management solutions tailored to aging companion animals
